Emergent BioSolutions Inc.
EBS
$8.50
-$0.45-5.03%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -29.75% | -23.63% | -21.34% | -44.68% | -26.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -29.75% | -23.63% | -21.34% | -44.68% | -26.03% |
| Cost of Revenue | -19.69% | -23.58% | -23.61% | -74.95% | -35.71% |
| Gross Profit | -38.38% | -23.71% | -19.55% | 192.67% | -15.06% |
| SG&A Expenses | -11.07% | -12.87% | -57.06% | -43.08% | -38.21% |
| Depreciation & Amortization | 1.23% | 0.00% | 0.00% | -0.61% | 0.62% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.06% | -18.04% | -32.11% | -66.07% | -34.27% |
| Operating Income | -79.17% | -58.04% | 6.46% | 100.31% | 27.89% |
| Income Before Tax | -85.54% | -83.70% | -59.55% | 93.77% | 666.12% |
| Income Tax Expenses | -73.28% | 5.41% | -76.81% | -136.09% | 696.77% |
| Earnings from Continuing Operations | -90.00% | -74.44% | -55.40% | 95.76% | 655.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.00% | -74.44% | -55.40% | 95.76% | 655.56% |
| EBIT | -79.17% | -58.04% | 6.46% | 100.31% | 27.89% |
| EBITDA | -55.75% | -100.91% | 2.41% | 117.87% | 13.32% |
| EPS Basic | -89.52% | -80.43% | -55.49% | 95.89% | 625.06% |
| Normalized Basic EPS | -71.24% | -42.31% | -28.58% | 90.63% | 290.13% |
| EPS Diluted | -93.76% | -79.75% | -55.83% | 95.89% | 600.00% |
| Normalized Diluted EPS | -72.18% | -42.31% | -29.59% | 90.63% | 270.32% |
| Average Basic Shares Outstanding | -4.60% | -3.32% | 0.19% | 3.04% | 4.21% |
| Average Diluted Shares Outstanding | -1.40% | -3.32% | 1.62% | 3.04% | 9.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |